ProAxsis confirms that new data on its ProteaseTag® technology will be presented at the American Thoracic Society Conference, which takes place …
ProAxsis confirms that new data on its ProteaseTag® technology will be presented at the American Thoracic Society Conference, which takes place …
ProAxsis Limited (www.proaxsis.com) today announces that it has successfully registered a CE Mark for its ProteaseTag® Active Plasmin Immunoassay. This novel technology …
Having reached the first anniversary following relocation to its new purpose-built laboratory on the Catalyst Inc. site in the Titanic Quarter of …
ProAxsis will be presenting further data on its ProteaseTag® technology, at the North American Cystic Fibrosis Conference, which takes place between …
ProAxsis Limited has contracted with National Jewish Health (NJH), the leading respiratory hospital in the United States, to validate the company’s …
ProAxsis today announces that the company has appointed Diagenics Limited as the distributor for its ProteaseTag® Active Neutrophil Elastase Immunoassay in Great …
ProAxsis Ltd today announces that the company has signed a partnership agreement to develop activity-based immunoassays for two key respiratory proteases, …
ProAxsis will be presenting further data on its ProteaseTag® technology, at the European Respiratory Society Conference, which takes place between September 9th-13thin …
Following its previous success in the BioMedical Catalyst competition, ProAxsis Limited (www.proaxsis.com) has now gained further support for its ProteaseTag® technology, via …
ProAxsis Ltd is delighted to observe that its ProteaseTag® Active Neutrophil Elastase Immunoassay is prominently featured in the most recent edition of …
ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland
tel +44 (0)28 9073 0444
email info@proaxsis.com